Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACAD Sold 5000 $15 JAN19 PUT contracts and bought 5000 $27 Jan19 CALL contracts.
I admired it because the trade basically cost him nothing to put on by using the money he got paid on the PUTS he financed the cost of buying the calls. Of course this "Big Dog" obviously has the deep pockets necessary to satisfy the margin requirements of a trade this large.Re: JAN 2019 strike 27 vol.1.5 MILLION dollars risk at 1.80 vol. 7954
Dead board now from Top of the boards . oOPS
What happened to this board? DEAD now . WOW
$IMMU New filing last week babay PBYI
https://www.sec.gov/Archives/edgar/data/722830/000090266417003965/xslF345X03/p17-2058form4.xml
TRXC when the filing new 510K > anyone knows? thnx
Could Idera Pharmaceuticals Inc (NASDAQ:IDRA) Be Sitting On a Blockbuster
Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a small cap bio-pharmaceutical company that may be sitting on something big, at least some traders are banking on it. There’s nothing that excites investors more than the idea that they might have found the next great biopharmaceutical stock. And that’s exactly what Massachusetts-based Idera Pharmaceuticals Inc (NASDAQ:IDRA) could turn out to be. This Boston-area company is well-funded, has a promising pipeline of new drug candidates, and has earned plaudits for its two innovative drug discovery technology platforms.
Based on this rising optimism about prospects for the company, shares of IDRA are up 66% YTD. Shares are currently trading at $2.49, which gives the company a total stock market capitalization of $444.94 million. Over the most recent 52-week period, shares have traded as low as $1.19 and as high as $3.33.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares have seen unusually high trading volume during the week of March 20. For example, on March 20, 2.82 million shares traded hands, compared to the typical daily average of 1.07 million shares. Then, on March 21, another 2.75 million shares traded hands. Typically, these spikes in trading volume are a bullish signal for investors.
And that’s not all – all the technical indicators for the stock are also lining up. The 50-day SMA for IDRA is $1.67 and the 200-day SMA is $1.77. Shares of IDRA are trading well above both of these short-term moving averages.
So what’s driving all this movement in IDRA activity? One near-term catalyst was the company releasing generally favorable 4Q results on March 15. Net income for the quarter was $0.82 million, compared to a net loss of $12.0 million in the year-earlier quarter. For the full year 2016, the company reported a net loss of $38.4 million, compared to a net loss of $48.6 million in 2015.
Before you get too excited about those rapidly improving financials, though, keep in mind that the company entered into a licensing agreement with Vivelix Pharmaceuticals for the worldwide rights to IMO-9200, one of the company’s most promising drug candidates. Vivelix Pharmaceuticals made an upfront payment of $15 million in November 2016, which obviously impacted 4Q and full-year results.
But here’s the important point to keep in mind – IDRA actually has four great drug candidates, and IMO-9200 wasn’t even the best candidate. It would be like a professional sports team holding on to its best 2-3 prospects, and getting a nice return on its third- or fourth-best prospect.
The two drug candidates that everyone’s excited about are IMO-8400 and IMO-2125. It’s this second drug, which offers a treatment for refractory melanoma, that some investors think could become a blockbuster drug. So, IDRA still has full control of IMO-2125 and IMO-8400, and things are looking very good indeed for both of them.
In fact, it’s the company’s two innovative drug discovery platforms, which keep churning out new drug candidates, that are the real assets here. The first of these drug discovery technology platforms is an immuno-oncology program based on Toll-Like Receptor (TLR) targeting technology. And the second of these drug discovery technology programs involves third-generation antisense (3GA) technology.
At the beginning of 2017, the company had $100 million in cash, making it extremely well-funded. It has enough cash to extend its R&D runway to the second half of 2018.
There are just so many positives here. The company appears to have a strong pipeline of promising new drug candidates. It has a strong cash position to build out its R&D activities in 2017-2018. It has a veteran management team. And it has a next-generation, best-of-breed technology platform.
Going forward, investors will be keeping their eyes on the clinical results for IMO-2125. This is the most promising of all the drug candidates. It’s a product of the 3GA discovery platform, which focuses on turning off messenger RNA associated with disease-causing genes.
On March 22, JMP Securities came out with a “Market Outperform” rating for the stock. The research note also highlighted “a host of promising drug candidates.” And, most importantly, it set a near-term price target of $8 for IDRA. That represents a nearly threefold increase in the company’s current stock price ($2.49).
Clearly, good things could lie ahead for Idera Pharmaceuticals. Assuming the clinical trials continue to show good results, the only question is when, not if, the stock takes off again.
http://oracledispatch.com/2017/03/23/idera-pharmaceuticals-inc-nasdaqidra-sitting-blockbuster/
IDRA JMP Securities initiates coverage on Idera Pharmaceuticals (NASDAQ: IDRA) with a Market Outperform rating and a price target of $8.00.
Analyst Mike King Jr. comments "Founded on the basis of pioneering work in the field of antisense oligonucleotides, Idera boasts a best-ofbreed nucleic acid therapeutic platform that, in our opinion, is capable of generating a host of promising drug candidates. The company has recently made a strategic pivot into immuno-oncology with its lead IO asset, IMO-2125, which has exhibited impressive clinical activity in combination with checkpoint inhibition in the setting of anti-PD-1 refractory metastatic melanoma. Idera’s innovative platform, strong scientific foundation, seasoned management team, and assets with demonstrated clinical activity combine to make the company an attractive investment opportunity in the small-cap biotech space, in our opinion."
$IMMU announces publication of results for candidate in breast cancer Immunomedics' lead antibody-drug conjugate sacituzumab govitecan was highly active in heavily-pretreated patients with metastatic triple-negative breast cancer who received a median of five lines of therapy since diagnosis. Results from this single-arm Phase 2 study were published online in the Journal of Clinical Oncology. Among the 69 enrolled patients reported in the article, the overall confirmed objective response rate, with a cutoff as of August 2, 2016, was 30% (21 of 69), with two patients having complete remissions and 19 patients achieving partial responses. Overall, 69.5% of patients experienced a reduction of tumor burden. 13 of the 21 confirmed responders demonstrated a PR or better at the first response assessment at 8 weeks. Despite being a heavily pre-treated population, the median progression-free survival was 6.0 months and the median overall survival was 16.6 months. Anecdotal observation suggests that the ADC and PD-1/PD-L1 antibodies may represent non-cross-resistant therapeutic options for a potential combination therapy, which requires further study. The patients tolerated prolonged therapy with up to 67 doses of IMMU-132 given over 23 months, and there was no evidence of an immune response to the ADC. There were no life-threatening or fatal events related to treatment, and the toxicity profile was generally mild and manageable.
Read more at:
http://thefly.com/landingPageNews.php?id=2520353
OPHT my bad . please Ignore , its 2016 dated, sorry
$CYCC kevin tang loading up. HE KNOWS? ??
$SYRS ex-GEVA ceo is Director presenting AACR April 5
http://ir.syros.com/phoenix.zhtml?c=254294&p=irol-newsArticle&ID=2250829
$IDRA big event April 3rd https://www.smartpatients.com/trials/NCT02644967
$BIVV rev, 800M mkt cap 4 Bill. ACTIVIST target
$AGLE Orbimed Advisors bought 109,300 shares at $5.04-5.36 worth ~ $600K
$IDRA is a steal under 2 IMO. I am bag holder from 3.30 . baker bros on board justbluke INCY was 2 in 2009/
My ROTH IRA account full of IDRA
$IMMU radar on activist fund involved in it. Same funs bought TSRO and SRPT BEFORE big runs . it might be sold out . I am long Jan 2018 calla strike 3.50 at 1.10
BCDA merger PHASE 3 now .13c OPK ceo bought 65% of company
http://www.biocardia.com/product_pipeline/
KERX PRQR next week alert link here
http://www.insidermonkey.com/blog/here-are-two-dates-to-keep-an-eye-on-in-biotech-across-the-next-two-weeks-482409/
ACAD a/h vol. 282k http://www.nasdaq.com/symbol/acad/after-hours
$IDRA 50 million Dilution is great news for future developments but I wished they had partnered other Bio for cash rather than dilution .
$IDRA 2.56 November Presentation coming up
http://www.media-server.com/m/acs/a348f31fd34b940d4cdc3ca95cf1e225
$PTIE Pdufa 09/25/2016
$ACOR stroke data due soon OCT 27 calls OI 5300 https://clinicaltrials.gov/ct2/show/NCT02271217
In March 2015, the Company accepted Securities Purchase Agreements representing investor commitments totaling $15,000,000 in a private
placement offering of 16,304,350 shares of the Company’s common stock at a purchase price of $0.92 per share. The purchasers included all
seven members of the Board and Dr. Roger Kornberg, the Company’s Chief Scientist.
On March 9, 2016, the Company sold $5,004,370 of shares of common stock in a private placement offering to investors who participated in
the March 2015 private placement on a pro-rata basis to their participation in the March 2015 private placement. The Company sold
9,812,491 shares of the Company’s common stock at a purchase price of $0.51 per share. The purchasers included all seven members of the
Board
COCP Dr. Frost $VRUS guy in it uplisting Nasdaq soon
https://clinicaltrials.gov/ct2/show/NCT02760758?term=CC-31244&rank=1
$LXRX Lexicon has a busy second half of the year with an expected FDA decision on its Telotristat etiprate, and top-line results from two Phase 3 clinical trials of sotagliflozin in patients with type 1 diabetes. Telotristat etiprate is the first investigational drug in clinical studies to target tryptophan hydroxylase, the rate-limiting enzyme involved in serotonin production. Earlier this year, the FDA accepted the company's NDA filing, granting priority review and establishing a Prescription Drug User Fee Act target action date of November 30. In addition, the European Medicines Agency recently accepted a marketing authorization application filed for telotristat etiprate by Ipsen (IPSEY). Separately, the company is developing Sotagliflozin as a potential treatment for type 1 and type 2 diabetes. Lexicon is conducting three Phase 3 clinical trials of sotagliflozin in patients with type 1 diabetes, two of which have completed enrollment and are expected to provide top-line results in the second half of 2016.
$ITCI Intra-Cellular Therapies is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. Patient enrollment in ITI-007-302, the second Phase 3 clinical trial of ITI-007 in schizophrenia, was completed in the second quarter of 2016 and the company anticipates topline data from this trial will be available later this year. Separately, the company expects to provide more details regarding its clinical development plans for its ITI-214 program, the lead compound in the phosphodiesterase platform, later this year.
$TXMD In July, TherapeuticsMD submitted a New Drug Application with the FDA for Yuvvexy, the conditionally approved trade name for TX-004HR, the company’s applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate- to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy due to menopause. The NDA is supported by the complete Yuvvexy clinical program, including positive results of the recently completed phase 3 Rejoice Trial. The submission included all three doses of Yuvvexy (4 mcg, 10 mcg and 25 mcg) that were evaluated in the Rejoice Trial. Based on a traditional FDA timeline, the company should hear back by September 7th on whether the agency will reject or accept the application for review. Separately, the company anticipates topline results in the fourth quarter of 2016 for the ongoing Replenish Trial, a phase 3 clinical trial of the company’s TX-001HR product candidate, which, if approved, would be the first and only FDA-approved bio-identical combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms due to menopause
$ACHN Achillion Pharmaceuticals (ACHN) announces that interim results from an ongoing phase 2a clinical trial, being conducted by Alios BioPharma, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to evaluate all-oral combination regimens, containing odalasvir, AL-335 and simeprevir, were accepted for presentation at the EASL -- American Association for the Study of Liver Diseases (AASLD) Special Conference: New Perspectives in Hepatitis C Virus Infection -- The Roadmap for Cure, being hosted in Paris, France on September 23 -- 24, 2016.
PBYI i) reporting additional data from the Phase II trial of neratinib as an extended adjuvant treatment in HER2-positive early stage breast cancer using loperamide prophylaxis in [4Q16]; (ii) reporting additional Phase II data from the FB-7 neoadjuvant HER2-positive breast cancer trial in the subgroup of patients who are MammaPrint High in [4Q16]; (iii) reporting data from the Phase II trial of neratinib plus fulvestrant in patients with HER2 non-amplified breast cancer that has a HER2 mutation during [4Q16]; (iv) reporting data from the Phase III trial of neratinib in third-line HER2-positive metastatic breast cancer patients in either [4Q16] or [1Q17]; and (v) reporting data from the Phase II trial of neratinib in metastatic breast cancer patients with brain metastases during [4Q16].
WOW! PT for $CYCC of $60 and upside to $173 by HC Wainwright. Could be a good trader today off of this https://t.co/3MXQXK3USN
$PTN Thursday, August 11th, 2016 at 1:00 p.m. Eastern time. The conference is being held at the InterContinental Boston, Boston, MA August 10-11, 2016.
$PTN clinicaltrial show 2 phase3 trial Link https://clinicaltrials.gov/ct2/results?term=palatin&Search=Search
PTN phase 3 in next 4-8 weeks Female viagra https://clinicaltrials.gov/ct2/show/NCT02338960?term=palatin&rank=1
$ARWR $BMRN unsual call activity. Keep Radar (No Positin though )
I am big big BAGHOLDER for $IDRA from 3.33 but I averaged down to 2.28 now. in 2017 It had 4 data coming up and It could be next CPXX in 18 months.
$RSPI Sleep APNEA 43 MILLION possible patients
http://wgnradio.com/2014/09/30/dina-bairs-medical-watch-taking-a-pill-to-stop-sleep-apnea/